Erasca, Inc. (ERAS) Latest Company News

Sep 15, 2026, 13:07 UTC
Grabar Law Office announced it is investigating whether certain officers and directors of Erasca, Inc. breached their fiduciary duties owed to the company and its shareholders.
Source:
- globenewswire.com
Sep 10, 2026, 12:00 UTC
Erasca, Inc. announced that updated monotherapy clinical data from the Phase 1 AURORAS-1 trial of ERAS-0015 and nonclinical combination data of ERAS-0015 and ERAS-4001 will be presented at the 38th EORTC-NCI-AACR Symposium in Barcelona on November 18-20, 2026.
Source:
- globenewswire.com
Aug 26, 2026, 13:26 UTC
Bernstein Liebhard LLP announced an investigation into potential breaches of fiduciary duty by directors and officers of Erasca, Inc.
Source:
- newsfilecorp.com
Aug 24, 2026, 12:00 UTC
The U.S. Food and Drug Administration granted Fast Track Designation to Erasca's ERAS-0015 for the treatment of patients with metastatic pancreatic adenocarcinoma.
Source:
- globenewswire.com
Aug 5, 2026, 17:45 UTC
A class action lawsuit has been filed against Erasca, Inc. on behalf of investors who purchased Erasca securities between January 14, 2025 and April 26, 2026.
Source:
Jul 14, 2026, 23:40 UTC
Erasca Inc. reported positive phase 1 clinical trial results for its drug candidate ERAS-0015 in treating RAS-mutant solid tumors, showing tumor shrinkage in pancreatic cancer patients.
Source:
- finance.yahoo.com
- benzinga.com
Jul 13, 2026, 20:19 UTC
Erasca announced a proposed public offering of $500 million of its common stock.
Source:
Jul 4, 2026, 15:57 UTC
A class action lawsuit has been filed against Erasca, Inc. in connection with alleged securities fraud or other unlawful business practices.
Source:
Jun 25, 2026, 14:19 UTC
Nathan Austad was sentenced to 18 months in federal prison for his role in a 2022 credential stuffing attack on DraftKings that compromised about 60,000 accounts and caused hundreds of thousands of dollars in losses.
Source:
- cyberscoop.com
Jun 24, 2026, 13:24 UTC
A shareholder filed a securities class action lawsuit against Erasca, Inc. in the U.S. District Court for the Southern District of New York on behalf of investors who purchased Erasca common stock between January 14, 2025 and April 26, 2026.
Source:
- globenewswire.com

ERAS

Grabar Law Office announced it is investigating whether certain officers and directors of Erasca, Inc. breached their fiduciary duties owed to the company and its shareholders.

Erasca, Inc. announced that updated monotherapy clinical data from the Phase 1 AURORAS-1 trial of ERAS-0015 and nonclinical combination data of ERAS-0015 and ERAS-4001 will be presented at the 38th EORTC-NCI-AACR Symposium in Barcelona on November 18-20, 2026.

Bernstein Liebhard LLP announced an investigation into potential breaches of fiduciary duty by directors and officers of Erasca, Inc.

The U.S. Food and Drug Administration granted Fast Track Designation to Erasca's ERAS-0015 for the treatment of patients with metastatic pancreatic adenocarcinoma.

A class action lawsuit has been filed against Erasca, Inc. on behalf of investors who purchased Erasca securities between January 14, 2025 and April 26, 2026.

Erasca Inc. reported positive phase 1 clinical trial results for its drug candidate ERAS-0015 in treating RAS-mutant solid tumors, showing tumor shrinkage in pancreatic cancer patients.

Erasca announced a proposed public offering of $500 million of its common stock.

A class action lawsuit has been filed against Erasca, Inc. in connection with alleged securities fraud or other unlawful business practices.

Nathan Austad was sentenced to 18 months in federal prison for his role in a 2022 credential stuffing attack on DraftKings that compromised about 60,000 accounts and caused hundreds of thousands of dollars in losses.

A shareholder filed a securities class action lawsuit against Erasca, Inc. in the U.S. District Court for the Southern District of New York on behalf of investors who purchased Erasca common stock between January 14, 2025 and April 26, 2026.